Navigation Links
Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
Date:2/24/2009

KANSAS CITY, Mo., Feb. 24 /PRNewswire/ -- An investor group in Trinity Biotech plc (Nasdaq: TRIB), an Irish based developer and manufacturer of diagnostic products, has petitioned the Office of the Director of Corporate Enforcement to facilitate compliance with key company law provisions designed to permit communication between shareholders and prospective shareholders.

The petition as filed asserts that Irish-based independent directors, Peter Coyne of Allied Irish Bank, and Dr. Jim Walsh, together with Chairman and CEO, Ronan O'Caoimh have breached Irish Company Law by blocking access to information requested by shareholders wishing to convert ADRs (American Depository Receipts) to the Irish shares they represent. The investor group has requested ODCE support of a formal investigation of the above named individuals for violation of Company Law and to pursue corrective action against this illegal behavior.

Commenting on the news, Mr. Reidy stated, "We are disappointed that the current Board has disregarded not only the wishes of shareholders but its obligations to respond to shareholder requests for the calling of an EGM (Extraordinary General Meeting). We are particularly displeased by the board's refusal to provide periodic notification of changes in registered ownership of company shares, which we view as a basic right protected under Irish securities law."

Contact: Tom Reidy, 816-260-8476, tjreidy3@hotmail.com


'/>"/>
SOURCE KC Investor Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
2. Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
3. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
4. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
5. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
6. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
7. BioMS Medical to present at BIO CEO and Investor Conference
8. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
11. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):